Description
Simmitinib is an investigational drug currently being studied as a potential treatment for advanced solid tumors, including colorectal cancer. It is being tested in combination with another investigational drug called SG001. Clinical trials are in the early phase (Phase 1), focusing on determining the safest dose and looking at early signs of effectiveness. The trials are evaluating simmitinib in patients whose tumors have specific characteristics, such as being MSI-H (microsatellite instability-high) or having certain levels of PD-L1 expression. Simmitinib is a type of targeted therapy, meaning it aims to interfere with specific molecules involved in cancer cell growth or survival.
Mechanism of Action
Simmitinib is being developed as a targeted therapy. It works by targeting specific proteins involved in tumor growth and survival pathways. The specific molecular target is being characterized in clinical trials. It is being studied in combination with SG001 to see if this combination can effectively treat advanced solid tumors.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.